Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

141 Articles

Chris Lange | Apr 24, 2016 at 10:35 AM EDT

4 Companies That Have Destroyed Shareholders

Although the markets have made their comeback, some stocks are still slowing that recovery and punishing their shareholders. Last week…

Chris Lange | Apr 24, 2016 at 10:10 AM EDT

Why Key Analyst Sees Huge Upside in Sarepta Therapeutics

Sarepta Therapeutics shares got crushed on Thursday and then exploded on Friday following the FDA view on its Duchenne muscular…

Jon C. Ogg | Apr 20, 2016 at 8:50 AM EDT

Top Analyst Upgrades and Downgrades: ArcelorMittal, Boeing, Intel, Schlumberger, Yahoo, Vivint Solar, Johnson & Johnson and More

The top analyst upgrades, downgrades and initiations seen on Wednesday morning include ArcelorMittal, Boeing, Intel, Johnson & Johnson, Schlumberger, Yahoo…

Lee Jackson | Mar 20, 2016 at 10:15 AM EDT

Massive Biotech and Bill Gates Trades Highlight Insider Buying: Seattle Genetics, Ecolab, Sarepta Therapeutics and More

After a week when the indexes finally fought their way back to even for 2016, one probably would think that…

Chris Lange | Jan 31, 2016 at 10:20 AM EST

3 Key FDA Decisions Expected in February

24/7 Wall St. has collected three big FDA decisions coming up in February and added some color, along with the…

Jon C. Ogg | Jan 19, 2016 at 8:55 AM EST

Top Analyst Upgrades and Downgrades: IBM, Lennar, Regions, Shake Shack, Shopify, TerraForm, McDonald’s and Many More

Stocks tanked on Friday but were indicated sharply higher on Tuesday after the three-day weekend and after China’s gross domestic…

Chris Lange | Jan 16, 2016 at 10:25 AM EST

5 Stocks That Punished Shareholders Last Week

While these were not the five biggest absolute losers of the week, of the active stocks, these all issued news…

Chris Lange | Jan 15, 2016 at 10:05 AM EST

Why Sarepta Therapeutics Is Cratering

Sarepta Therapeutics plunged early on Friday as the result of a failed clinical trial by BioMarin Pharmaceutical.

Lee Jackson | Dec 2, 2015 at 10:20 AM EST

4 Top Jefferies Biotech and Specialty Pharma Growth Stocks to Buy Now

A new Jefferies research report focuses on some biotech and specialty pharmaceutical stocks that have had some headline and clinical…

Chris Lange | Nov 21, 2015 at 10:25 AM EST

6 BioHealth Movers That Now Cannot Be Ignored

24/7 Wall St. examines Valeant Pharmaceuticals and other biotech stocks with incredible gains or losses over the course of the…

Lee Jackson | Nov 20, 2015 at 9:35 AM EST

4 Biopharma and Pharmaceutical Stocks With Game-Changing Catalysts Coming

A new Jefferies research report highlights four top companies that could be looking at catalysts that in the very near…

Lee Jackson | Nov 6, 2015 at 8:25 AM EST

Wall Street Hammered These 3 Biotech Stocks: Are They Really Screaming Buys?

We combed through the Merrill Lynch database and found three biotech companies that at one time or another, when they…

Chris Lange | Oct 6, 2015 at 10:35 AM EDT

Why Sarepta Deserves Praise for Capital Raise Despite Stock Drop

Sarepta announced a public offering of more than 3 million shares of its common stock at a price to the…

Chris Lange | Oct 1, 2015 at 8:35 AM EDT

Sarepta Makes Headway With Phase 2 Program

Sarepta Therapeutics announced additional clinical efficacy and safety data from its Phase 2b program of eteplirsen in patients with Duchenne…

Jon C. Ogg | Aug 7, 2015 at 8:50 AM EDT

Top Analyst Upgrades and Downgrades: BankUnited, Barrick Gold, ConocoPhillips, Michael Kors, Mylan, Viacom, Disney and Many More

Friday's top analyst upgrades, downgrades and initiations include BankUnited, Barrick Gold, ConocoPhillips, Michael Kors, Mylan, Viacom and Disney.

1 … 5 6 7 8 9 10

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

4 Companies That Have Destroyed Shareholders

Why Key Analyst Sees Huge Upside in Sarepta Therapeutics

Top Analyst Upgrades and Downgrades: ArcelorMittal, Boeing, Intel, Schlumberger, Yahoo, Vivint Solar, Johnson & Johnson and More

Massive Biotech and Bill Gates Trades Highlight Insider Buying: Seattle Genetics, Ecolab, Sarepta Therapeutics and More

3 Key FDA Decisions Expected in February

Top Analyst Upgrades and Downgrades: IBM, Lennar, Regions, Shake Shack, Shopify, TerraForm, McDonald’s and Many More

5 Stocks That Punished Shareholders Last Week

Why Sarepta Therapeutics Is Cratering

4 Top Jefferies Biotech and Specialty Pharma Growth Stocks to Buy Now

6 BioHealth Movers That Now Cannot Be Ignored

4 Biopharma and Pharmaceutical Stocks With Game-Changing Catalysts Coming

Wall Street Hammered These 3 Biotech Stocks: Are They Really Screaming Buys?

Why Sarepta Deserves Praise for Capital Raise Despite Stock Drop

Sarepta Makes Headway With Phase 2 Program

Top Analyst Upgrades and Downgrades: BankUnited, Barrick Gold, ConocoPhillips, Michael Kors, Mylan, Viacom, Disney and Many More

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

4 Companies That Have Destroyed Shareholders

Why Key Analyst Sees Huge Upside in Sarepta Therapeutics

Top Analyst Upgrades and Downgrades: ArcelorMittal, Boeing, Intel, Schlumberger, Yahoo, Vivint Solar, Johnson & Johnson and More

Massive Biotech and Bill Gates Trades Highlight Insider Buying: Seattle Genetics, Ecolab, Sarepta Therapeutics and More

3 Key FDA Decisions Expected in February

Top Analyst Upgrades and Downgrades: IBM, Lennar, Regions, Shake Shack, Shopify, TerraForm, McDonald’s and Many More

5 Stocks That Punished Shareholders Last Week

Why Sarepta Therapeutics Is Cratering

4 Top Jefferies Biotech and Specialty Pharma Growth Stocks to Buy Now

6 BioHealth Movers That Now Cannot Be Ignored

4 Biopharma and Pharmaceutical Stocks With Game-Changing Catalysts Coming

Wall Street Hammered These 3 Biotech Stocks: Are They Really Screaming Buys?

Why Sarepta Deserves Praise for Capital Raise Despite Stock Drop

Sarepta Makes Headway With Phase 2 Program

Top Analyst Upgrades and Downgrades: BankUnited, Barrick Gold, ConocoPhillips, Michael Kors, Mylan, Viacom, Disney and Many More

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Featured Reads

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do